Artificial intelligence

By 2030, total knee replacement is projected to grow by up to 189%, according to the American Academy of Orthopaedic Surgeons, and 90% of people who receive one report less pain from chronic conditions such as arthritis.
The substantial cost of hip implant surgeries is one of the major factors expected to hamper the growth of the global market.
Otezla is Celgene's marketed oral drug for psoriasis and psoriatic arthritis that had sales of $1.6 billion in 2018, and that number is rising to $2.5 billion in 2023.
The rheumatoid arthritis and psoriasis markets are largely mature, but could see around $5 billion to $10 billion in expansion.
According to the Centers for Disease Control and Prevention (CDC), around 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040.
According to the projections by the CDC, an estimated 78 million people in the U.S. are going to be affected by some form of arthritis by the year 2040.
According to the Centers for Disease Control and Preventions (CDC), 25.9% of the adult population in the US will be diagnosed with Arthritis by 2040.
According to Centers for Disease Prevention and Control (CDC), an estimate of 78.4 million adults aged 18 years or above will have doctor-diagnosed arthritis by 2040 in the U.S., as compared to 54.4 million adults in 2013 to 2015.
In the United States, 54 million adults have some form of doctor-diagnosed arthritis , a number projected to increase to 78 million by 2040.
The world health organization predicts the prevalence of Rheumatoid Arthritis to be between 0.3% and 1% and more common in women and in developed countries.
The demand for wheelchairs from the geriatric population will extensively increase in the coming years: Market research analysts predict that this global market will register a revenue of more than USD5.4 billion by 2022.
By 2030 there will be 17 million people in the UK with arthritis and 3 million with cancer.
Global chronic pain treatment market is expected to witness considerable growth due to current unmet medical need of chronic pain.
A class of anti-inflammatory drugs already FDA-approved for rheumatoid arthritis could "purge" the reservoir of infected immune cells in people infected by HIV.
Middle East & Africa will grow at moderate rate in rheumatoid arthritis treatment market owing to factor the treatment cost is high for the disease.
Asia pacific will grow at highest CAGR over the forecast period in rheumatoid arthritis treatment market owing to factors like increasing healthcare expenditure, rising obese population, and increasing cigarette consumption in the region.
Rheumatoid arthritis treatment market will show immense growth as there is rise in FDA approvals to the rheumatoid arthritis drugs.
Global market for apoptosis related products is expected to grow at a high CAGR of about 30% through 2022.
Asia-Pacific is expected to be the fastest growing region in the global foot and ankle devices market.
North America is expected dominate the global foot and ankle devices market in the coming years.
Autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.
The idea of targeting the nervous system to control the immune system could potentially be used to treat conditions such as rheumatoid arthritis, autoimmune disease, cancer.

See full forecast

Last updated: 10 November 2019